Common Side Effects Based on Clinical Trial According to the OASIS clinical trials, the most commonly reported side effects included nausea, diarrhea, vomiting, and constipation
Wegovy, a GLP-1 medication used for weight loss, is now also available as an oral tablet that you take by mouth once per day
These treatments reduce hunger, increase fullness, and optimize your bodys natural weight management processes
Approval status is night and day: tirzepatide is FDA-approved (Mounjaro in 2022, Zepbound in 2023), while retatrutide is still working through Phase 3
Mounjaro (branded as Zepbound for weight loss) is a slow-to-break-down version of both GLP-1 and the similar hormone GIP (glucose-dependent insulinotropic polypeptide)
That means compounded versions of semaglutide the active ingredient in Novo Nordisk's Ozempic and Rybelsus for diabetes and obesity therapy Wegovy are already in the market